{"id":"altretamine","rwe":[],"tags":[{"label":"Alkylating Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 1A2","category":"target"},{"label":"CYP1A2","category":"gene"},{"label":"L01XX03","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Malignant tumor of ovary","category":"indication"},{"label":"Eisai Inc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[],"contraindications":["Anemia","Ataxia","Bone marrow depression","Breastfeeding (mother)","Leukopenia","Mood swings","Peripheral nerve disease","Pregnancy, function","Severe Bone Marrow Depression","Thrombocytopenic disorder","Unconscious","Vertigo"]},"trials":[],"aliases":[],"company":"Eisai","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALTRETAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:21:07.764260+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Altretamine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:21:16.010645+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:21:14.665135+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALTRETAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:21:15.402370+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:16.010015+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1455/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:15.901315+00:00"}},"allNames":"hexalen","offLabel":[],"synonyms":["altretamine","hexalen","hexamethylmelamine","hexylen"],"timeline":[{"date":"1990-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from EISAI INC to Eisai Inc"},{"date":"1990-12-26","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eisai Inc)"}],"aiSummary":"Hexalen (Altretamine) is a small molecule alkylating drug developed by Eisai Inc, targeting Cytochrome P450 1A2. It was FDA-approved in 1990 for the treatment of malignant ovarian tumors. As an off-patent medication, Hexalen is no longer protected by active patents, allowing for potential generic competition. Despite its off-patent status, Eisai Inc remains the current owner of the medication. Key safety considerations include the need for careful monitoring of patients due to potential side effects.","brandName":"Hexalen","ecosystem":[{"indication":"Malignant tumor of ovary","otherDrugs":[{"name":"carboplatin","slug":"carboplatin","company":""},{"name":"cisplatin","slug":"cisplatin","company":"Hq Spclt Pharma"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"gemcitabine","slug":"gemcitabine","company":"Lilly"}],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 1A2","novelty":"Follow-on","targets":[{"gene":"CYP1A2","source":"DrugCentral","target":"Cytochrome P450 1A2","protein":"Cytochrome P450 1A2"}],"moaClass":"Alkylating Activity","modality":"Small Molecule","drugClass":"Alkylating Drug","explanation":"","oneSentence":"","technicalDetail":"Hexalen (Altretamine) exerts its cytotoxic effects through the alkylation of DNA, specifically targeting the N7 position of guanine, which leads to DNA strand breaks and inhibition of DNA replication and transcription."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Altretamine","title":"Altretamine","extract":"Altretamine, also called hexamethylmelamine, is an antineoplastic agent. It was approved by the U.S. FDA in 1990."},"commercial":{"launchDate":"1990","_launchSource":"DrugCentral (FDA 1990-12-26, EISAI INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/141","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALTRETAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALTRETAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Altretamine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:39:16.564735","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:17.816306+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"asparaginase","drugSlug":"asparaginase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"hydroxycarbamide","drugSlug":"hydroxycarbamide","fdaApproval":"1967-12-07","relationship":"same-class"},{"drugName":"pentostatin","drugSlug":"pentostatin","fdaApproval":"1991-10-11","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mitotane","drugSlug":"mitotane","fdaApproval":"1970-07-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaspargase","drugSlug":"pegaspargase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"denileukin diftitox","drugSlug":"denileukin-diftitox","fdaApproval":"1999-02-05","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"anagrelide","drugSlug":"anagrelide","fdaApproval":"1997-03-14","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"omacetaxine mepesuccinate","drugSlug":"omacetaxine-mepesuccinate","fdaApproval":"2012-10-26","patentExpiry":"Oct 26, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eribulin","drugSlug":"eribulin","fdaApproval":"2010-11-15","patentExpiry":"Jul 8, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"venetoclax","drugSlug":"venetoclax","fdaApproval":"2016-04-11","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enasidenib","drugSlug":"enasidenib","fdaApproval":"2017-08-01","patentExpiry":"Sep 16, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivosidenib","drugSlug":"ivosidenib","fdaApproval":"2018-07-20","patentExpiry":"Oct 18, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selinexor","drugSlug":"selinexor","fdaApproval":"2019-07-03","patentExpiry":"Jul 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tagraxofusp","drugSlug":"tagraxofusp","fdaApproval":"2018-12-21","relationship":"same-class"},{"drugName":"lurbinectedin","drugSlug":"lurbinectedin","fdaApproval":"2020-06-15","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tazemetostat","drugSlug":"tazemetostat","fdaApproval":"2020-01-23","patentExpiry":"Sep 12, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"altretamine","indications":{"approved":[{"name":"Malignant tumor of ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Eisai Inc","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"asparaginase","brandName":"asparaginase","genericName":"asparaginase","approvalYear":"1994","relationship":"same-class"},{"drugId":"hydroxycarbamide","brandName":"hydroxycarbamide","genericName":"hydroxycarbamide","approvalYear":"1967","relationship":"same-class"},{"drugId":"pentostatin","brandName":"pentostatin","genericName":"pentostatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mitotane","brandName":"mitotane","genericName":"mitotane","approvalYear":"1970","relationship":"same-class"},{"drugId":"pegaspargase","brandName":"pegaspargase","genericName":"pegaspargase","approvalYear":"1994","relationship":"same-class"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-class"},{"drugId":"denileukin-diftitox","brandName":"denileukin diftitox","genericName":"denileukin diftitox","approvalYear":"1999","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"},{"drugId":"anagrelide","brandName":"anagrelide","genericName":"anagrelide","approvalYear":"1997","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":["Malaria"],"enrollment":400,"completionDate":"2026-11-30"},{"nctId":"NCT06905834","phase":"PHASE2","title":"Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2026-05","conditions":["Dry Eye Disease (DED)","Graft-Versus-Host Disease(GVHD)"],"enrollment":30,"completionDate":"2028-06"},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":["Non-ischemic Dilated Cardiomyopathy"],"enrollment":136,"completionDate":"2027-04"},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":["Malaria,Falciparum"],"enrollment":360,"completionDate":"2026-12"},{"nctId":"NCT05249374","phase":"PHASE1","title":"Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects","status":"COMPLETED","sponsor":"Protgen Ltd","startDate":"2021-10-14","conditions":["Hepatic Ascites"],"enrollment":36,"completionDate":"2022-05-16"},{"nctId":"NCT07354321","phase":"","title":"Thrombo-inflammation in Acute Neurovascular Diseases: Definition of New Therapeutic Targets (TARGETS)","status":"NOT_YET_RECRUITING","sponsor":"François Delvoye","startDate":"2026-02","conditions":["Delayed Cerebral Ischemia After Subarachnoid Hemorrhage","Ischemic Stroke of Large or Medium Vessels"],"enrollment":499,"completionDate":"2032-12"},{"nctId":"NCT04057833","phase":"PHASE1","title":"E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-11-20","conditions":["Rotator Cuff Tears","Muscle Atrophy or Weakness","Tendon Rupture - Shoulder","Safety Issues"],"enrollment":20,"completionDate":"2026-10"},{"nctId":"NCT02495896","phase":"PHASE1","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2015-09-03","conditions":["Head and Neck Squamous Cell Carcinoma","Metastatic Pancreatic Adenocarcinoma","Non-Resectable Cholangiocarcinoma","Pancreatic Adenocarcinoma","Recurrent Gallbladder Carcinoma","Recurrent Non-Small Cell Lung Carcinoma","Stage III Pancreatic Cancer","Stage IIIA Gallbladder Cancer","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Gallbladder Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Gallbladder Cancer","Stage IV Non-Small Cell Lung Cancer","Stage IV Pancreatic Cancer","Unresectable Gallbladder Carcinoma","Unresectable Pancreatic Cancer"],"enrollment":61,"completionDate":"2026-04-01"},{"nctId":"NCT03049618","phase":"PHASE2","title":"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2017-03-10","conditions":["ALK Gene Mutation","BRAF Gene Mutation","EGFR Gene Mutation","Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Carcinoma","Recurrent Head and Neck Carcinoma","Recurrent Non-Small Cell Lung Carcinoma","ROS1 Gene Mutation","Stage III Non-Small Cell Lung Cancer","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer"],"enrollment":42,"completionDate":"2024-09-04"},{"nctId":"NCT05854641","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":["Critical Limb Ischemia","Peripheral Arterial Disease"],"enrollment":10,"completionDate":"2027-12"},{"nctId":"NCT05854615","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":["Critical Limb Ischemia","Buerger's Disease"],"enrollment":3,"completionDate":"2027-12"},{"nctId":"NCT06432582","phase":"","title":"hepatomiR cACLD Study","status":"RECRUITING","sponsor":"Karl Landsteiner University of Health Sciences","startDate":"2024-05-15","conditions":["Chronic Liver Disease and Cirrhosis","Chronic Liver Disease","Portal Hypertension"],"enrollment":156,"completionDate":"2026-06"},{"nctId":"NCT04869397","phase":"PHASE2","title":"Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-14","conditions":["Covid19"],"enrollment":19,"completionDate":"2023-05-26"},{"nctId":"NCT04776239","phase":"PHASE1,PHASE2","title":"Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)","status":"COMPLETED","sponsor":"Joshua M Hare","startDate":"2021-08-16","conditions":["Diabetes Mellitus","Ischemic Heart Disease"],"enrollment":26,"completionDate":"2025-08-26"},{"nctId":"NCT01192555","phase":"PHASE1,PHASE2","title":"Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2010-09","conditions":["Neuroblastoma"],"enrollment":11,"completionDate":"2026-09"},{"nctId":"NCT06299163","phase":"PHASE1","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","status":"TERMINATED","sponsor":"Numab Therapeutics AG","startDate":"2024-05-01","conditions":["Ovarian Carcinoma","Fallopian Tube Carcinoma","Peritoneal Carcinoma","Endometrial Cancer","Adenocarcinoma of Lung","Triple Negative Breast Cancer","Liposarcoma","Leiomyosarcoma","Mesothelioma, Malignant","Adenocarcinoma - Gastroesophageal Junction (GEJ)","Adenocarcinoma of the Stomach","Melanoma, Malignant","Renal Cell Carcinoma"],"enrollment":11,"completionDate":"2025-04-18"},{"nctId":"NCT04832607","phase":"PHASE3","title":"Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections","status":"RECRUITING","sponsor":"Tobias Feuchtinger","startDate":"2019-08-27","conditions":["AdV Infection","EBV Infection","CMV Infection","Stem Cell Transplant Complications"],"enrollment":149,"completionDate":"2028-09"},{"nctId":"NCT00199862","phase":"NA","title":"Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-02","conditions":["Colorectal Neoplasms","Colorectal Cancer","Colorectal Tumor","COlorectal Carcinoma"],"enrollment":30,"completionDate":"2025-07-02"},{"nctId":"NCT02717156","phase":"PHASE2","title":"Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2016-11-21","conditions":["Stage IV Bladder Urothelial Carcinoma","Prostate Cancer","Urothelial Carcinoma"],"enrollment":103,"completionDate":"2026-11-21"},{"nctId":"NCT04442126","phase":"PHASE1,PHASE2","title":"A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Numab Therapeutics AG","startDate":"2020-08-19","conditions":["Advanced Solid Tumor","Non-small Cell Lung Cancer","Colorectal Cancer","Squamous Cell Carcinoma","Ovarian Carcinoma","Peritoneal Carcinoma","Fallopian Tube Cancer","Head and Neck Squamous Cell Carcinoma","Triple Negative Breast Cancer"],"enrollment":52,"completionDate":"2024-02-06"},{"nctId":"NCT05775211","phase":"NA","title":"Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations","status":"RECRUITING","sponsor":"Nadezhda Women's Health Hospital","startDate":"2023-03-13","conditions":["Infertility"],"enrollment":300,"completionDate":"2026-04-28"},{"nctId":"NCT05775198","phase":"NA","title":"Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome","status":"RECRUITING","sponsor":"Nadezhda Women's Health Hospital","startDate":"2023-03-01","conditions":["Infertility, Female","IVF"],"enrollment":300,"completionDate":"2026-04-28"},{"nctId":"NCT05421364","phase":"NA","title":"Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations","status":"RECRUITING","sponsor":"Nadezhda Women's Health Hospital","startDate":"2023-12-09","conditions":["Female Infertility"],"enrollment":300,"completionDate":"2026-12-09"},{"nctId":"NCT02799485","phase":"PHASE2","title":"sEphB4-HSA in Treating Patients With Kaposi Sarcoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2018-02-13","conditions":["Skin Kaposi Sarcoma"],"enrollment":23,"completionDate":"2025-02-19"},{"nctId":"NCT06493552","phase":"PHASE2,PHASE3","title":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","status":"RECRUITING","sponsor":"Vasgene Therapeutics, Inc","startDate":"2025-03-15","conditions":["Muscle-Invasive Bladder Carcinoma","Metastatic Urothelial Carcinoma"],"enrollment":700,"completionDate":"2034-08"},{"nctId":"NCT06035744","phase":"PHASE1","title":"CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Cullinan Therapeutics Inc.","startDate":"2023-12-12","conditions":["Advanced Solid Tumor"],"enrollment":86,"completionDate":"2028-06"},{"nctId":"NCT04091867","phase":"PHASE1","title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-06","conditions":["Squamous Cell Carcinoma of Head and Neck"],"enrollment":3,"completionDate":"2022-10-25"},{"nctId":"NCT01705899","phase":"PHASE1","title":"Islet Allotransplantation in Type 1 Diabetes","status":"SUSPENDED","sponsor":"Ohio State University","startDate":"2006-11","conditions":["Type 1 Diabetes"],"enrollment":20,"completionDate":"2033-10"},{"nctId":"NCT04456478","phase":"NA","title":"Impact of PH Values of the Embryo Culture Medium on Success of in Vitro Fertilization (IVF)","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2020-10-14","conditions":["Embryo Growth Disorder","Humans","Pregnancy"],"enrollment":429,"completionDate":"2024-06-19"},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":["GVHD, Acute"],"enrollment":50,"completionDate":"2031-12-31"},{"nctId":"NCT05042076","phase":"PHASE1","title":"BK With VST for Kidney Transplant Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":["Kidney Transplant Infection","BK Virus Infection"],"enrollment":3,"completionDate":"2024-05-14"},{"nctId":"NCT06716788","phase":"","title":"68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-01","conditions":["Cancer"],"enrollment":50,"completionDate":"2026-05-31"},{"nctId":"NCT05604521","phase":"PHASE1","title":"A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI","status":"TERMINATED","sponsor":"Sanaria Inc.","startDate":"2022-12-06","conditions":["Malaria","Malaria,Falciparum"],"enrollment":31,"completionDate":"2023-09-05"},{"nctId":"NCT04285892","phase":"NA","title":"Embryo Developmental Potential in a Novel 2-step IVM System","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-07-16","conditions":["In Vitro Maturation of Oocytes"],"enrollment":23,"completionDate":"2023-12-31"},{"nctId":"NCT03798301","phase":"PHASE1","title":"Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2020-02-06","conditions":["CMV Infection","Cytomegalovirus Infections","CMV Viremia","Opportunistic Infections"],"enrollment":3,"completionDate":"2023-05-31"},{"nctId":"NCT06145035","phase":"PHASE2","title":"Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"Roberto Bolli","startDate":"2024-03-04","conditions":["Ischemic Heart Disease"],"enrollment":60,"completionDate":"2026-01-01"},{"nctId":"NCT03175536","phase":"","title":"Asthma in Families Facing Out-of-pocket Requirements With Deductibles","status":"COMPLETED","sponsor":"Harvard Pilgrim Health Care","startDate":"2017-03-01","conditions":["Asthma"],"enrollment":12238,"completionDate":"2021-04-30"},{"nctId":"NCT04931823","phase":"PHASE1","title":"Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2021-03-24","conditions":["Solid Tumor"],"enrollment":126,"completionDate":"2025-03-01"},{"nctId":"NCT06531902","phase":"","title":"LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-10-01","conditions":["Colorectal Cancer"],"enrollment":88,"completionDate":"2021-06-01"},{"nctId":"NCT04484077","phase":"PHASE1","title":"hCT-MSC Infusion in Adults With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Joanne Kurtzberg, MD","startDate":"2022-01-24","conditions":["Autism Spectrum Disorder","Autism"],"enrollment":8,"completionDate":"2024-04-29"},{"nctId":"NCT06427278","phase":"","title":"Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-08-01","conditions":["Colorectal Cancer"],"enrollment":90,"completionDate":"2023-01-01"},{"nctId":"NCT03993106","phase":"PHASE2","title":"A Study of sEphB4-HSA in Kaposi Sarcoma","status":"RECRUITING","sponsor":"Vasgene Therapeutics, Inc","startDate":"2020-09-17","conditions":["Kaposi Sarcoma"],"enrollment":65,"completionDate":"2025-06"},{"nctId":"NCT04486781","phase":"PHASE2","title":"A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Vasgene Therapeutics, Inc","startDate":"2020-08-14","conditions":["Metastatic Urothelial Carcinoma"],"enrollment":38,"completionDate":"2025-12-31"},{"nctId":"NCT05836623","phase":"PHASE1","title":"A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions","status":"UNKNOWN","sponsor":"Crescendo Biologics Ltd.","startDate":"2022-12-20","conditions":["Advanced and/or Metastatic Solid Tumours"],"enrollment":5,"completionDate":"2024-10-31"},{"nctId":"NCT06276517","phase":"","title":"Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03","conditions":["Intracranial Hemorrhages"],"enrollment":80,"completionDate":"2028-03"},{"nctId":"NCT03950414","phase":"PHASE1","title":"A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-09-27","conditions":["Cytomegalovirus Infections","Solid Organ Transplant"],"enrollment":2,"completionDate":"2022-07-11"},{"nctId":"NCT06144268","phase":"NA","title":"Live Birth Rate After Sperm Selection Using ZyMōt Multi (850µL) Device for Intra Uterine Insemination","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2024-01-10","conditions":["Infertility","Fertility Disorders"],"enrollment":240,"completionDate":"2027-12"},{"nctId":"NCT06219096","phase":"NA","title":"Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2023-12-10","conditions":["Malignant Tumor of Liver","Randomized Controlled Trial"],"enrollment":100,"completionDate":"2028-12-31"},{"nctId":"NCT05346120","phase":"PHASE2","title":"Post-Acute COVID-19, Inflammation, and Depression","status":"WITHDRAWN","sponsor":"Sean Savitz","startDate":"2022-05-25","conditions":["Post COVID -19 Depression"],"enrollment":0,"completionDate":"2024-05-01"},{"nctId":"NCT06157619","phase":"","title":"Vitrification of Oocytes Matured by CAPA-IVM","status":"UNKNOWN","sponsor":"Centro de Fertilidad y Reproducción Asistida, Peru","startDate":"2023-12","conditions":["Fertility Preservation"],"enrollment":20,"completionDate":"2025-03"},{"nctId":"NCT04839991","phase":"PHASE1","title":"Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.","status":"UNKNOWN","sponsor":"Crescendo Biologics Ltd.","startDate":"2021-06-08","conditions":["Advanced and/or Metastatic Solid Tumours"],"enrollment":70,"completionDate":"2024-09-25"},{"nctId":"NCT04660396","phase":"","title":"Monitoring Outpatient Blood VolumE in Heart Failure","status":"COMPLETED","sponsor":"Daxor Corporation","startDate":"2021-09-16","conditions":["Heart Failure"],"enrollment":15,"completionDate":"2022-07-30"},{"nctId":"NCT03451916","phase":"PHASE3","title":"Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)","status":"COMPLETED","sponsor":"Pluristem Ltd.","startDate":"2018-07-26","conditions":["Hip Fracture"],"enrollment":240,"completionDate":"2023-09-06"},{"nctId":"NCT03591614","phase":"EARLY_PHASE1","title":"Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-12-01","conditions":["Monoclonal Gammopathy","Smoldering Myeloma","Myeloma"],"enrollment":0,"completionDate":"2025-08-01"},{"nctId":"NCT03552796","phase":"PHASE1","title":"sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2023-08-01","conditions":["Recurrent Bladder Carcinoma","Bladder Cancer Stage 0","Bladder Cancer Stage I"],"enrollment":0,"completionDate":"2025-08-01"},{"nctId":"NCT04547699","phase":"NA","title":"Cytokines Supplementation to Culture Media and ICSI Outcome","status":"COMPLETED","sponsor":"Mansoura Integrated Fertility Center","startDate":"2020-02-01","conditions":["ICSI"],"enrollment":700,"completionDate":"2022-07-01"},{"nctId":"NCT05568953","phase":"PHASE2","title":"An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2022-09-28","conditions":["Infectious Disease","Yellow Fever","Japanese Encephalitis","Viral Infection"],"enrollment":70,"completionDate":"2025-10"},{"nctId":"NCT02587572","phase":"PHASE2","title":"Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial","status":"WITHDRAWN","sponsor":"Longeveron Inc.","startDate":"2023-12-01","conditions":["Metabolic Disease","Endothelial Dysfunction"],"enrollment":0,"completionDate":"2023-12"},{"nctId":"NCT05624827","phase":"NA","title":"The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)","status":"UNKNOWN","sponsor":"University Medical Centre Maribor","startDate":"2021-09-01","conditions":["Cervical Intraepithelial Neoplasia Grade 2","DNA Methylation"],"enrollment":100,"completionDate":"2024-05-01"},{"nctId":"NCT05548101","phase":"NA","title":"Prospective, Randomized Trial Comparing ICSI to Insemination for Non-Male Factor Patients Undergoing PGT-A","status":"UNKNOWN","sponsor":"Texas Fertility Center","startDate":"2022-11-01","conditions":["Infertility"],"enrollment":500,"completionDate":"2023-11-01"},{"nctId":"NCT01642342","phase":"PHASE1","title":"Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2012-09-06","conditions":["Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":102,"completionDate":"2019-05-29"},{"nctId":"NCT04916431","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-28","conditions":["Healthy Volunteers"],"enrollment":18,"completionDate":"2022-08-02"},{"nctId":"NCT04033432","phase":"PHASE2","title":"sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2019-09-20","conditions":["Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents","Metastatic Prostate Adenocarcinoma","Progressive Disease","Prostate Carcinoma Metastatic in the Bone","Prostate Carcinoma Metastatic in the Soft Tissue","PSA Progression","Stage IVB Prostate Cancer AJCC v8","Testosterone Less Than 50 ng/dL"],"enrollment":14,"completionDate":"2022-06-30"},{"nctId":"NCT05179174","phase":"","title":"The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma","status":"UNKNOWN","sponsor":"University of Catania","startDate":"2021-04-20","conditions":["Uveal Melanoma"],"enrollment":102,"completionDate":"2023-12"},{"nctId":"NCT02600130","phase":"PHASE1","title":"Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Longeveron Inc.","startDate":"2016-10-10","conditions":["Alzheimer's Disease"],"enrollment":33,"completionDate":"2021-09"},{"nctId":"NCT03519984","phase":"PHASE1","title":"EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2018-05-09","conditions":["Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Blasts 5 Percent or More of Bone Marrow Nucleated Cells","Myelodysplastic/Myeloproliferative Neoplasm","Philadelphia Chromosome Positive","Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Secondary Acute Myeloid Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":3,"completionDate":"2020-11-24"},{"nctId":"NCT02767921","phase":"PHASE1","title":"sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2016-08-02","conditions":["Infiltrating Bladder Urothelial Carcinoma","Recurrent Bladder Carcinoma","Stage I Prostate Cancer","Stage I Renal Cell Cancer","Stage II Bladder Urothelial Carcinoma","Stage II Renal Cell Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer","Stage III Renal Cell Cancer"],"enrollment":2,"completionDate":"2021-11-15"},{"nctId":"NCT04835480","phase":"PHASE2","title":"A Phase II Study of OsrHSA in Patients With Decompensated Cirrhotic Ascites","status":"RECRUITING","sponsor":"Healthgen Biotechnology Corp.","startDate":"2021-03-22","conditions":["Cirrhotic Ascites"],"enrollment":220,"completionDate":"2022-06-30"},{"nctId":"NCT01989897","phase":"PHASE1,PHASE2","title":"Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests","status":"WITHDRAWN","sponsor":"Bryan Martin, DO","startDate":"2013-03","conditions":["Allergic Rhinitis"],"enrollment":0,"completionDate":"2015-11"},{"nctId":"NCT05080543","phase":"PHASE1","title":"Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients","status":"UNKNOWN","sponsor":"Amany Mousa Salama Muhammed","startDate":"2021-10","conditions":["Septic Shock"],"enrollment":36,"completionDate":"2022-10"},{"nctId":"NCT04549285","phase":"PHASE1","title":"Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome","status":"WITHDRAWN","sponsor":"Joanne Kurtzberg, MD","startDate":"2021-03-12","conditions":["Multisystem Inflammatory Syndrome in Children"],"enrollment":0,"completionDate":"2022-02-01"},{"nctId":"NCT01394978","phase":"NA","title":"NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2011-06","conditions":["Lung Cancer","Lung Tumor"],"enrollment":444,"completionDate":"2016-02"},{"nctId":"NCT03915054","phase":"NA","title":"Amphiregulin Versus Non-Amphiregulin Supplementation to Maturation Culturing Medium in IVM.","status":"COMPLETED","sponsor":"Mỹ Đức Hospital","startDate":"2019-04-17","conditions":["PCOS","IVM"],"enrollment":30,"completionDate":"2020-01-31"},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":["Malaria"],"enrollment":409,"completionDate":"2018-07-03"},{"nctId":"NCT04021095","phase":"NA","title":"Novel Head Protection Prototype Device for Decompression Craniectomy","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2019-07-04","conditions":["Brain Injuries","Stroke"],"enrollment":10,"completionDate":"2021-03-31"},{"nctId":"NCT02013700","phase":"PHASE1","title":"Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2013-11-13","conditions":["Idiopathic Pulmonary Fibrosis (IPF)"],"enrollment":9,"completionDate":"2016-11-24"},{"nctId":"NCT04641364","phase":"PHASE1","title":"Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2019-06-24","conditions":["Ascites"],"enrollment":80,"completionDate":"2020-05-06"},{"nctId":"NCT02503280","phase":"PHASE1,PHASE2","title":"The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.","status":"WITHDRAWN","sponsor":"Joshua M Hare","startDate":"2025-03-01","conditions":["Chronic Ischemic Left Ventricular Dysfunction","Myocardial Infarction"],"enrollment":0,"completionDate":"2032-03"},{"nctId":"NCT03114904","phase":"NA","title":"Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2016-02-27","conditions":["Withdrawal Syndrome","Cerebral Lesion"],"enrollment":8,"completionDate":"2018-05-16"},{"nctId":"NCT02754024","phase":"","title":"Humeral Head Implants: Radiological and Clinical Evaluation","status":"UNKNOWN","sponsor":"Werner Anderl","startDate":"2005-09","conditions":["Idiopathic Osteoarthritis","Posttraumatic Osteoarthritis","Humeral Head Necrosis","Instability Arthritis"],"enrollment":100,"completionDate":"2025-09"},{"nctId":"NCT03058068","phase":"PHASE1","title":"Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Joshua M Hare","startDate":"2020-12","conditions":["Cystic Fibrosis"],"enrollment":0,"completionDate":"2028-09"},{"nctId":"NCT00539656","phase":"PHASE1,PHASE2","title":"Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-12-20","conditions":["Acute Myeloid Leukemia","Leukemia, Lymphoblastic, Acute","Leukemia, Bilineage, Acute","Leukemia, Myeloid, Chronic"],"enrollment":3,"completionDate":"2009-10-20"},{"nctId":"NCT02015091","phase":"PHASE1","title":"Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-12-12","conditions":["Malaria"],"enrollment":141,"completionDate":"2016-09-08"},{"nctId":"NCT02570126","phase":"PHASE3","title":"A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-13","conditions":["Chicken-pox Illness (Varicella Virus Disease)","Chickenpox"],"enrollment":1236,"completionDate":"2016-10-25"},{"nctId":"NCT00587990","phase":"PHASE1,PHASE2","title":"Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2007-11","conditions":["Stem Cell Transplantation","Ventricular Dysfunction, Left"],"enrollment":9,"completionDate":"2011-06"},{"nctId":"NCT03146871","phase":"PHASE2","title":"Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-04-20","conditions":["Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Recurrent Adult Acute Myeloid Leukemia"],"enrollment":7,"completionDate":"2019-03-27"},{"nctId":"NCT03647033","phase":"NA","title":"Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2015-10-14","conditions":["Primary Angle-Closure Glaucoma","Primary Angle Closure Without Glaucoma Damage"],"enrollment":32,"completionDate":"2017-08-12"},{"nctId":"NCT00568334","phase":"PHASE2","title":"Study of Two Formulations of GSK Biologicals' Varicella Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-01","conditions":["Varicella"],"enrollment":244,"completionDate":"2008-04-29"},{"nctId":"NCT01686776","phase":"PHASE3","title":"A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA","status":"COMPLETED","sponsor":"Ake Norberg","startDate":"2012-09-27","conditions":["Healthy","SIRS"],"enrollment":30,"completionDate":"2013-06-01"},{"nctId":"NCT03404284","phase":"","title":"Assessment of Family Planning and Immunization Service Integration in Malawi","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2016-06","conditions":["Contraception","Contraceptive Usage","Contraception Behavior","Infant, Newborn, Diseases"],"enrollment":43,"completionDate":"2017-09"},{"nctId":"NCT02439398","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI","status":"COMPLETED","sponsor":"Coretherapix","startDate":"2014-06","conditions":["Acute Myocardial Infarction"],"enrollment":55,"completionDate":"2016-11-14"},{"nctId":"NCT02465801","phase":"PHASE2","title":"Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2014-12-16","conditions":["Chemotherapy-induced Neutropenia"],"enrollment":216,"completionDate":"2016-04-26"},{"nctId":"NCT01774097","phase":"PHASE2","title":"Patients With Intermittent Claudication Injected With ALDH Bright Cells","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-06","conditions":["Peripheral Artery Disease","Intermittent Claudication"],"enrollment":82,"completionDate":"2017-03"},{"nctId":"NCT00109278","phase":"PHASE2","title":"A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10","conditions":["Measles"],"enrollment":1100,"completionDate":"2005-05"},{"nctId":"NCT00092404","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-12","conditions":["Measles","Mumps","Rubella","Varicella"],"enrollment":1210,"completionDate":"2005-06"},{"nctId":"NCT03038035","phase":"PHASE2","title":"The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2016-12","conditions":["Alzheimer Disease"],"enrollment":150,"completionDate":"2019-06"},{"nctId":"NCT01521143","phase":"PHASE2","title":"Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment","status":"TERMINATED","sponsor":"Prima BioMed Ltd","startDate":"2012-01","conditions":["Epithelial Ovarian Cancer"],"enrollment":91,"completionDate":"2015-03"},{"nctId":"NCT02762760","phase":"PHASE1","title":"AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint","status":"COMPLETED","sponsor":"Ampio Pharmaceuticals. Inc.","startDate":"2016-05","conditions":["Osteoarthritis of the Hand"],"enrollment":15,"completionDate":"2016-11"},{"nctId":"NCT02931305","phase":"PHASE1","title":"Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2016-10","conditions":["Osteoporosis","Cardiovascular Disease"],"enrollment":30,"completionDate":"2017-10"},{"nctId":"NCT00550498","phase":"PHASE1","title":"Stem Cell Transplantation in Ocular Lesions of Behcet's Disease","status":"TERMINATED","sponsor":"Tehran University of Medical Sciences","startDate":"2007-12","conditions":["Retinitis","Behcet's Syndrome"],"enrollment":5,"completionDate":"2013-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000147673","MMSL":"4156","NDDF":"003567","UNII":"Q8BIH59O7H","VUID":"4019574","CHEBI":"CHEBI:24564","VANDF":"4019574","INN_ID":"4825","RXNORM":"153474","UMLSCUI":"C0019453","chemblId":"CHEMBL1455","ChEMBL_ID":"CHEMBL1455","KEGG_DRUG":"D02841","DRUGBANK_ID":"DB00488","PUBCHEM_CID":"2123","SNOMEDCT_US":"387385000","IUPHAR_LIGAND_ID":"7112","MESH_DESCRIPTOR_UI":"D006585"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1990-","companyName":"Eisai Inc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","fractionUnbound":"0.112%"},"publicationCount":64,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XX03","allCodes":["L01XX03"]},"biosimilarFilings":[],"originalDeveloper":"Eisai Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Eisai Inc","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"1990","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:17.816306+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}